

BURKINA FASO

Number of new cases

14 538

Number of deaths

10 998

Number of prevalent cases (5-year)

26 352


Statistics at a glance, 2022

	Males	Females	Both sexes
Population	11 056 571	11 046 267	22 102 838
Incidence*			
Number of new cancer cases	5 556	8 982	14 538
Age-standardized incidence rate	112.5	138.5	125.2
Risk of developing cancer before the age of 75 years (cum. risk %)	12.2	15.3	13.9
Top 3 leading cancers (ranked by cases)**	Prostate Liver Bladder	Breast Cervix uteri Liver	Liver Breast Prostate
Mortality*			
Number of cancer deaths	4 344	6 654	10 998
Age-standardized mortality rate	91.1	106.7	98.5
Risk of dying from cancer before the age of 75 years (cum. risk %)	9.8	12.2	11.1
Top 3 leading cancers (ranked by deaths)**	Liver Prostate Bladder	Breast Liver Cervix uteri	Liver Breast Cervix uteri
Prevalence*			
5-year prevalent cases	9 610	16 742	26 352



Top 5 most frequent cancers**


Males



Rank	Cancer site	Number of cases	Percent
1st	Prostate	1 152	20.7%
2nd	Liver	1 109	20.0%
3rd	Bladder	459	8.3%
4th	Leukaemia	326	5.9%
5th	Pancreas	234	4.2%
-	Others	2 276	41.0%

Number of new cases in 2022, males, all ages


Females



Rank	Cancer site	Number of cases	Percent
1st	Breast	1 372	15.3%
2nd	Cervix uteri	988	11.0%
3rd	Liver	821	9.1%
4th	Ovary	552	6.1%
5th	Bladder	532	5.9%
-	Others	4 717	52.5%

Number of new cases in 2022, females, all ages

Both sexes



Rank	Cancer site	Number of cases	Percent
1st	Liver	1 930	13.3%
2nd	Breast	1 372	9.4%
3rd	Prostate	1 152	7.9%
4th	Bladder	991	6.8%
5th	Cervix uteri	988	6.8%
-	Others	8 105	55.8%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Liver	1 930	1	13.3	1.9	1 864	1	16.9	1.9	2 963	13.4
Breast	1 372	2	9.4	2.4	818	2	7.4	1.5	2 674	24.2
Prostate	1 152	3	7.9	4.0	772	4	7.0	2.5	1 666	15.1
Bladder	991	4	6.8	1.2	580	6	5.3	0.74	1 952	8.8
Cervix uteri	988	5	6.8	2.0	775	3	7.0	1.6	1 913	17.3
Pancreas	704	6	4.8	0.73	655	5	6.0	0.68	1 008	4.6
Leukaemia	649	7	4.5	0.31	468	7	4.3	0.27	1 357	6.1
Ovary	552	8	3.8	0.95	432	8	3.9	0.83	985	8.9
Colorectum	460	9	3.2	0.31	362	9	3.3	0.24	847	3.8
NHL	380	10	2.6	0.25	253	14	2.3	0.20	798	3.6
Kidney	369	11	2.5	0.17	229	15	2.1	0.12	795	3.6
Stomach	363	12	2.5	0.55	343	10	3.1	0.52	597	2.7
Corpus uteri	362	13	2.5	1.0	121	18	1.1	0.44	782	7.1
Brain CNS	361	14	2.5	0.28	305	12	2.8	0.27	829	3.8
Lung	351	15	2.4	0.51	340	11	3.1	0.49	544	2.5
Oesophagus	319	16	2.2	0.45	300	13	2.7	0.42	525	2.4
Lip, oral cavity	221	17	1.5	0.24	166	16	1.5	0.19	425	1.9
Multiple myeloma	166	18	1.1	0.21	143	17	1.3	0.19	315	1.4
Salivary glands	107	19	0.74	0.14	65	19	0.59	0.11	232	1.1
Kaposi sarcoma	95	20	0.65	0.05	65	19	0.59	0.04	166	0.75
Larynx	90	21	0.62	0.13	58	21	0.53	0.08	171	0.77
Thyroid	84	22	0.58	0.14	44	22	0.40	0.09	164	0.74
Gallbladder	42	23	0.29	0.07	38	23	0.35	0.06	63	0.29
Vulva	41	24	0.28	0.04	26	24	0.24	0.03	89	0.81
Hodgkin lymphoma	33	25	0.23	0.01	18	28	0.16	0.01	76	0.34
Melanoma	29	26	0.20	0.04	11	30	0.10	0.02	64	0.29
Vagina	29	26	0.20	0.06	22	25	0.20	0.04	55	0.50
Testis	27	28	0.19	0.02	22	25	0.20	0.01	61	0.55
Hypopharynx	25	29	0.17	0.02	20	27	0.18	0.02	39	0.18
Oropharynx	23	30	0.16	0.02	14	29	0.13	0.02	37	0.17
Mesothelioma	16	31	0.11	0.00	0	31	0.00	0.00	0	0.00
Nasopharynx	0	32	0.00	0.00	0	31	0.00	0.00	0	0.00
All cancers	14 538	-	-	13.9	10 998	-	-	11.1	26 352	-
All cancers excl. NMSC	14 308	-	-	13.7	10 903	-	-	11.0	25 857	-

Data source and methods

Incidence

Country-specific data source:

Method: "All sites" estimates from neighbouring countries partitioned using frequency data



Mortality

Country-specific data source: No data

Method: Estimated from national incidence estimates by modelling, using mortality:incidence ratios derived from survival estimation

Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



* includes non-melanoma skin cancer (NMSC)

** NMSC included in other cancers

Age standardization using world population ([see link](#))

References

Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

